Raymond James maintains BridgeBio Pharma at 'outperform' with a price target of $46.00

  • Investing.com
Raymond James maintains BridgeBio Pharma at 'outperform' with a price target of $46.00

An analyst from Raymond James maintained BridgeBio Pharma (NASDAQ: BBIO ) at 'outperform' with a price target of $46.00 from a prior price target of %currency%%price%.

Prior to this rating, BridgeBio Pharma had 11 buy ratings, 0 hold ratings, and 0 sell ratings.

For consensus analyst estimates and price targets on BridgeBio Pharma, click here. For more news on BridgeBio Pharma, click here.

BridgeBio Pharma's stock price closed at $32.04. They are up 0% in the last month and up 234.45% in the last 12 months.

According to Investing Pro, BridgeBio Pharma's fair value is $13.99, a downside of 56.32%. BridgeBio Pharma's fair value comes with a high degree of uncertainty, according to InvestingPro.

Check out BridgeBio Pharma's recent earnings performance and financials here.

Drop an image here or Supported formats: *.jpg, *.png, *.gif up to 5mb

Error: File type not supported

Drop an image here or

100

Related Articles